paclitaxel

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

With the new devices (drug-eluting balloons [DEB], drug-eluting stents [DES], and atherotomes) percutaneous treatment is becoming the first line of approach for femoropopliteal disease, especially when dealing with not very long total occlusions. Randomized studies and registries on the use of drug-coated balloons (DCB) in femoropopliteal disease are currently available, but their evolution beyond 2<a href="https://solaci.org/en/2023/01/30/in-pact-study-should-we-start-using-dcbs-more-frequently-in-cases-of-femoropopliteal-disease/" title="Read more" >...</a>

The Most Important Articles of 2022 in Peripheral Vascular Disease

Discover the most important scientific articles of 2022 in peripheral vascular disease in our website. EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.&nbsp; Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal<a href="https://solaci.org/en/2023/01/19/the-most-important-articles-of-2022-in-peripheral-vascular-disease/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Drug Coated Balloons in Femoropopliteal Territory: Predictors of Failed Patency

Endovascular treatment in femoropopliteal territory has become the strategy of choice over time, with diverse devices; among others, drug coated balloons (DCB). DBS are meant to provide the antiproliferation effect of drugs while reducing exposure of a specific artery segment to a strange body.&nbsp;&nbsp; Even though the number of studies on DCB effectiveness has been<a href="https://solaci.org/en/2022/11/04/drug-coated-balloons-in-femoropopliteal-territory-predictors-of-failed-patency/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling.&nbsp; Randomized studies have shown that the use of Paclitaxel drug eluting stents (DES) reduces the number of new revascularizations (even though these studies compared mostly against conventional balloons, which is why we<a href="https://solaci.org/en/2022/10/26/eminent-trial-stent-eluvia-vs-bms-in-femoropopliteal-territory/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SURTAVI at 5 Years

Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280&nbsp;patients and an 8&nbsp;year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>

A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone.&nbsp; However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

The New Sirolimus Eluting Balloons Are Also Effective

The technological development of drug eluting stents has allowed us to treat increasingly complex patients, with around 10% stenosis and using more, and longer stents.&nbsp; This situation generates a great challenge: keep using stents or use paclitaxel coated balloons (PCB). At present, there are sirolimus drug coated balloons (SCB), but we do not have enough<a href="https://solaci.org/en/2022/10/11/the-new-sirolimus-eluting-balloons-are-also-effective/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Use of OCT FFR on ACS Clinical Outcomes

Patients undergoing acute coronary syndrome (ACS) benefit from percutaneous coronary intervention (PCI). At present, there is no question about this. However, residual ischemia after PCI is associated with a worse prognosis. Angiography studies and intravascular imaging are useful to assess post intervention outcomes, but they are limited when it comes to the physiological assessment of<a href="https://solaci.org/en/2022/10/05/use-of-oct-ffr-on-acs-clinical-outcomes/" title="Read more" >...</a>

La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX<a href="https://solaci.org/en/2022/08/23/clinical-results-of-ivus-guided-drug-eluting-stent-implantation-in-femoropopliteal-disease/" title="Read more" >...</a>

Nuevas estrategias en el territorio femoropoplíteo

IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory

Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized studies have shown their effectiveness and benefit in femoropopliteal territory, and even though the use of paclitaxel coated balloons has been called into question, a retrospective study including 168,553 patients was able to show paclitaxel coated balloons were<a href="https://solaci.org/en/2022/06/27/in-pact-global-follow-up-of-real-life-patient-in-femoropopliteal-territory/" title="Read more" >...</a>

Top